What is TARGET RWE?
Founded in 2015 and headquartered in Durham, North Carolina, TARGET PharmaSolutions, now operating as TARGET RWE, is dedicated to enhancing clinical, scientific, and commercial outcomes for clinics. The company leverages real-world evidence (RWE) to drive improvements across the healthcare spectrum, positioning itself as a key player in the data-driven transformation of pharmaceutical research and patient care.
How much funding has TARGET RWE raised?
TARGET RWE has raised a total of $637K across 1 funding round:
Private Equity
$637K
Private Equity (2016): $637K, investors not publicly disclosed
What's next for TARGET RWE?
The substantial enterprise-level funding and recent strategic investment indicate a strong growth phase for TARGET RWE. This capital infusion is likely to fuel further expansion of its RWE platform, enhance its analytical capabilities, and broaden its market reach. The company is poised to deepen its impact on clinical trial optimization and commercial strategy development within the pharmaceutical industry, solidifying its role as a critical partner for healthcare organizations seeking to leverage real-world data.
See full TARGET RWE company page
